重度再生障碍性贫血患者使用艾曲泊帕治疗前后的医疗资源使用与直接成本数据集

数据集获取（Figshare）

• 源站标题：Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag
• DOI：10.6084/m9.figshare.10253300.v1
• 发布日期：2019-11-05
• 文件数：4 个
• 文件总体积：57.53 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Healthcare_resource_use_and_direct_costs_in_severe_aplastic_anemia_SAA_patients_before_and_after_treatment_with_eltrombopag/10253300

命令行下载

curl -L -o "ijme_a_1688820_sm3421.docx" "https://ndownloader.figshare.com/files/18514277"
curl -L -o "ijme_a_1688820_sm3420.docx" "https://ndownloader.figshare.com/files/18514280"
curl -L -o "ijme_a_1688820_sm3419.docx" "https://ndownloader.figshare.com/files/18514283"
curl -L -o "ijme_a_1688820_sm3418.docx" "https://ndownloader.figshare.com/files/18514286"

文件清单

• ijme_a_1688820_sm3421.docx（15.03 KB）
• ijme_a_1688820_sm3420.docx（14.18 KB）
• ijme_a_1688820_sm3419.docx（14.85 KB）
• ijme_a_1688820_sm3418.docx（13.47 KB）

文件总体积 57.53 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Purpose: This study evaluated healthcare resource utilization (HCRU), and direct costs among severe aplastic anemia (SAA) patients treated with eltrombopag (EPAG) using US claims data.
Methods: This retrospective, real-world claims database study identified SAA patients aged ≥2 years treated with EPAG who initiated any SAA treatment between 1 July 2014 and 31 December 2017 (identification period) using the Truven MarketScan databases. A subset of 82 patients treated with EPAG during the identification period were evaluated for all-cause and SAA-related HCRU and direct costs as well as blood transfusion 1 month before EPAG initiation (baseline) and at Month 6 after EPAG initiation (follow-up period).
Results: The average patient age was 50.8 (SD = 20.6) years old, predominantly female (n = 43, 52.4%), and had a mean CCI at baseline of 1.1 (SD = 1.7). Hospitalizations, and ER, office, and outpatient visits were significantly lower at Month 6 after EPAG initiation compared with 1 month before EPAG initiation (p SD]) were significantly higher at Month 6 after EPAG initiation compared with 1 month before EPAG initiation (difference of $11,045 USD [SD = $18,801]), these increases were offset by savings in direct costs. Overall, a mean reduction in total all-cause costs of $29,391 USD [SD = $137,770] was reported at Month 6 after EPAG initiation due to substantial reductions in hospitalization ($40,060 USD [SD = $123,198]) and outpatient visits ($2,043 USD [SD = $25,264]).
Conclusion: All-cause and SAA-related HCRU were reduced following EPAG treatment. Prescription costs were higher following treatment; however, these costs were generally offset by reductions in direct costs. These results provide real-world evidence around the role of EPAG in SAA treatment.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.10253300.v1（source: https://tandf.figshare.com/articles/dataset/Healthcare_resource_use_and_direct_costs_in_severe_aplastic_anemia_SAA_patients_before_and_after_treatment_with_eltrombopag/10253300）。